Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

  Location: https://investor.resmed.com
  Date: Wednesday, April 23, 2025
  Time: 1:30 p.m. PDT / 4:30 p.m. EDT
  International: London, Wednesday, April 23, 2025, 9:30 p.m. BST
      Sydney, Thursday, April 24, 2025, 6:30 a.m. AEST


Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.

A replay of the earnings webcast will be accessible on Resmed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from April 23, 2025, until May 7, 2025, at:

  U.S.: +1 877.660.6853
  International: +1 201.612.7415
  Conference ID: 13752711



About Resmed


Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

For investors
For media
+1 858.836.5000 +1 619.510.1281
[email protected] [email protected]
   



Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares

MONACO, April 02, 2025 (GLOBE NEWSWIRE) — Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today that the Company’s Board of Directors has declared:

  • a cash dividend of $0.50 per share on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares (the “Series C Preferred Shares”) (NYSE: SB.PR.C) for the period from January 30, 2025 to April 29, 2025;
  • a cash dividend of $0.50 per share on its 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares (the “Series D Preferred Shares”) (NYSE: SB.PR.D) for the period from January 30, 2025 to April 29, 2025.

Each dividend will be paid on April 30, 2025 to all shareholders of record as of April 17, 2025 of the Series C Preferred Shares and of the Series D Preferred Shares, respectively. Dividends on the Series C and D Preferred Shares are payable quarterly in arrears on the 30th day (unless the 30th falls on a weekend or public holiday, in which case the payment date is moved to the next business day) of January, April, July and October of each year.

The declaration and payment of future dividends, if any, will always be subject to the discretion of the Board of Directors of the Company. There is no guarantee that the Company’s Board of Directors will determine to issue cash dividends in the future. The timing and amount of any dividends declared will depend on, among other things: (i) the Company’s earnings, fleet employment profile, financial condition and cash requirements and available sources of liquidity; (ii) decisions in relation to the Company’s growth, fleet renewal and leverage strategies; (iii) provisions of Marshall Islands and Liberian law governing the payment of dividends; (iv) restrictive covenants in the Company’s existing and future debt instruments; and (v) global economic and financial conditions.

About Safe Bulkers, Inc.

The Company is an international provider of marine dry-bulk transportation services, transporting bulk cargoes, particularly grain, coal and iron ore, along worldwide shipping routes for some of the world’s largest users of marine dry-bulk transportation services. The Company’s common stock, series C preferred stock and series D preferred stock are listed on the NYSE, and trade under the symbols “SB”, “SB.PR.C”, and “SB.PR.D”, respectively.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Exchange Act of 1933, as amended, and in Section 21E of the Securities Act of 1934, as amended) concerning future events, the Company’s growth strategy and measures to implement such strategy, including expected vessel acquisitions and entering into further time charters. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, changes in the demand for drybulk vessels, competitive factors in the market in which the Company operates, risks associated with operations outside the United States and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information please contact:


Company Contact:

Dr. Loukas Barmparis
President
Safe Bulkers, Inc.
Tel.: +30 2 111 888 400
+357 25 887 200
E-Mail: [email protected]


Investor Relations / Media Contact:

Nicolas Bornozis, President
Capital Link, Inc.
230 Park Avenue, Suite 1536
New York, N.Y. 10169
Tel.: (212) 661-7566
Fax: (212) 661-7526
E-Mail: [email protected]



Duluth Holdings Inc. Announces Stephanie Pugliese as President and CEO

MOUNT HOREB, Wis., April 02, 2025 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading” or the “Company”) (NASDAQ: DLTH), a lifestyle brand of men’s and women’s workwear, casual wear, outdoor apparel, and accessories, today announced the appointment of Stephanie Pugliese as its President and Chief Executive Officer and as a member of the Board of Directors, effective May 5, 2025.

“We are delighted to welcome Stephanie back to Duluth Trading as our President and CEO,” said Stephen L. Schlecht, Chairman of Duluth Trading. “Following our initial public offering and during her previous tenure as President and CEO from 2015 through 2019, Stephanie was instrumental in leading our most successful period to date, doubling net sales and enhancing overall profitability.”

Mr. Schlecht added, “Stephanie’s intimate understanding of our brand ethos, solution-based products, and customer-centric philosophy ensures she will make an immediate impact. Her exceptional experience and expertise in leading brand-focused consumer businesses will be invaluable as we drive toward sustainable and profitable growth. Over the past several years, Duluth has made significant investments in systems, sourcing, and distribution that will serve as a strong foundation as we work to deliver differentiated products and an excellent customer experience.”

About Stephanie Pugliese

A 30-year retail veteran, Ms. Pugliese brings a wealth of branded apparel, retail, and merchandising experience to the Company. She first joined Duluth Trading in November 2008 as Vice President of Product and Merchandising. In July 2010, Ms. Pugliese was promoted to Senior Vice President, Head of Merchandising and Chief Marketing Officer. In February 2012, she was promoted to President and Chief Marketing Officer. From February 2014 to February 2015, Ms. Pugliese served as President and Chief Operating Officer, and from February 2015 to August 2019, Ms. Pugliese served as President and CEO of Duluth Trading.

From September 2019 to May 2020, Ms. Pugliese served as President of North America for Under Armour, Inc. and as its President of the Americas from June 2020 until March 2023. Ms. Pugliese joined the board of Fortune Brands Innovations, Inc. in March 2023 and served on the American Eagle Outfitters board from August 2024 to April 2025. She also currently serves on the Advisory Board of the Women in Retail Leadership Circle and Cooper’s Hawk Winery and Restaurants. Earlier in her career, Ms. Pugliese held several executive positions with Lands’ End, Inc. from 2005 to 2008 and Ann, Inc. from 2000 to 2003. Ms. Pugliese holds a Bachelor of Science degree in Marketing from New York University Stern School of Business.

Ms. Pugliese said, “I am incredibly excited to be rejoining Duluth Trading at this pivotal time in its journey to profitable growth. I know from my long tenure at the company spanning merchandising, marketing and leadership roles what a special brand it is and I am honored that Steve and the Board are giving me the opportunity to once again lead this talented team.”

About Duluth Trading

Duluth Trading is a lifestyle brand for the Modern, Self-Reliant American. Based in Mount Horeb, Wisconsin, we offer high quality, solution-based casual wear, workwear, and accessories for men and women who lead a hands-on lifestyle and who value a job well-done. We provide our customers an engaging and entertaining experience. Our marketing incorporates humor and storytelling that conveys the uniqueness of our products in a distinctive, fun way, and are available through our content-rich website, catalogs, and “store like no other” retail locations. We are committed to outstanding customer service backed by our “No Bull Guarantee” – if it’s not right, we’ll fix it. Visit our website at http://www.duluthtrading.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are not historical facts, and are based upon Duluth Trading’s current expectations, beliefs, estimates, and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond Duluth Trading’s control. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. Forward-looking statements speak only as of the date the statements are made. Duluth Trading assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances or other changes affecting forward-looking information except to the extent required by applicable securities laws.



Investor Contact:
Tom Filandro
ICR, Inc.
(646) 277-1200
[email protected]

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update.

“As part of Cyclacel’s efforts to reduce operating costs, it has determined to focus on the development of plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies, which we acquired on March 10, 2025, from Cyclacel Limited, our wholly-owned subsidiary that is currently in liquidation,” said Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer and Executive Director. “Our new, alternative salt, oral formulation of plogosertib with improved bioavailability is under development.”

“The commencement of the liquidation of Cyclacel Limited means that the Company will no longer have control over Cyclacel Limited and its financial results will be deconsolidated from those of the Company; as a result, the Company anticipates a significant decrease to research and development expenses for the year ended December 31, 2025 as we focus on our plogosertib clinical program and have no expenditures related to fadraciclib,” said Kiu Cu Seng, Chief Financial Officer. “The deconsolidation of Cyclacel Limited, which is anticipated to increase stockholders’ equity by approximately $5.0 million, will be reported in the Company’s Form 10-Q for the three months ended March 31, 2025.”

Financial Highlights

As of December 31, 2024, pro forma cash and cash equivalents totaled $7.2 million, including $4.1 million of equity financing received after the end of the year. Cash and cash equivalents as of December 31, 2024, totaled $3.1 million, compared to $3.4 million as of December 31, 2023. Net cash used in operating activities was $8.0 million for the twelve months ended December 31, 2024 compared to $16.1 million for the same period of 2023. The Company estimates that its available cash, including the equity financing of $4.1 million, will fund currently planned activities into the second quarter of 2025.

Research and development (R&D) expenses were $0.9 million and $6.7 million for the three months and year ended December 31, 2024, as compared to $3.5 million and $19.2 million for the same period in 2023. R&D expenses relating to fadraciclib were $0.8 million and $5.0 million for the three months and year ended December 31, 2024, as compared to $2.7 million and $13.4 million for the same period in 2023 due to decrease in clinical trial and other non-clinical expenditures. R&D expenses related to plogosertib were $0.1 million and $1.6 million for the three months and year ended December 31, 2024, as compared to $0.7 million and $5.0 million for the same period in 2023 due to decrease in clinical trial and other non-clinical expenditures.

General and administrative expenses for the three months and year ended December 31, 2024, were $0.9 million and $5.4 million, compared to $1.9 million and $6.7 million for the same period of the previous year due to a decrease in stock compensation and professional and corporate fees.

Total other income, net, for the three months and year ended December 31, 2024, were an expense of $30,000 and income of $10,000, compared to an expense of $333,000 and $98,000 for the same period of the previous year, due to foreign exchange movements.

United Kingdom research & development tax credits for the three months and year ended December 31, 2024 were a debit of $1.2 million and a credit of 0.8 million compared to credits $0.4 million and $3.0 million for the same period of the previous year and are directly correlated to qualifying research and development expenditure.

Net loss for the three months and year ended December 31, 2024, was $3.0 million and $11.2 million (including stock based compensation expense of $0.1 million and $0.6 million respectively), compared to $5.3 million and $22.6 million (including stock based compensation expense of $0.3 million and $1.5 million respectively) for the same period in 2023.

Board and Committee Appointments

On April 2, 2025, coinciding with the effective time of the previously announced resignations of Avraham Ben-Tzvi and David Natan, as independent directors, the Company appointed Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, as independent directors, on the Company’s board of directors (the “Board”) to fill the vacancies.

Dr. Satis Waran Nair Krishnan (age 39) is a Medical Doctor at Centric Health in Drogheda, County Louth, Ireland. Dr. Krishnan is a highly experienced practitioner originally from Malaysia. Dr. Krishnan joined Centric Health in Ireland September 2023. Prior to that, from 2010 to August 2023, Dr. Krishnan was a Doctor in the public health field for the Ministry of Health Malaysia, With a decade of practice in Malaysia and training in Dermatology from the Association of Family Physicians of Malaysia (AFPM) and the Institute of Dermatology in Bangkok, Thailand, Dr. Krishnan brings a wealth of expertise to our team. Dr. Nair is proficient in English, Russian and Ukrainian, he is dedicated to providing patient-centered care and promoting overall well-being. Dr. Krishnan received his medical degree in 2010 and Professional Diploma of General Dermatology in 2023.

Inigo Angel Laurduraj (age 40) brings extensive audit and accounting services to the Company over her 20 years in that industry. Ms. Laurduraj served as a Senior Accounting Manager at IOI Oleochemicals Sdn. Bhd., an edible oil refining and Oleochemicals company for 11 years from 2007 through 2018. Prior to that, she served from 2005 through 2005 as an Auditor for Moore Stephens (now Moore Global), a global firm operating in 114 countries specializing in accounting and finance services, audit and assurance, fund services, private client services, corporate services, and tax services. Ms. Laurduraj earned an Association of Chartered Certified Accountants (ACCA) in 2015 and a Bachelors of Arts in Accounting in 2014.

In connection with Ms. Laurduraj and Dr. Krishnan’s appointment, as well as the Board’s recent appointment of Mr. Kwang Fock Chong as independent director, on April 2, 2025, the Board also approved the following committee appointments:

  • Audit Committee — Kwang Fock Chong (Chair); Inigo Angel Laurduraj; and Dr. Satis Waran Nair Krishnan
  • Compensation Committee — Inigo Angel Laurduraj (Chair); Kwang Fock Chong; and Dr. Satis Waran Nair Krishnan
  • Governance Committee — Dr. Satis Waran Nair Krishnan (Chair), Kwang Fock Chong and Inigo Angel Laurduraj

The Company wishes to express its gratitude to the departing directors for their dedicated service and their support of Cyclacel’s efforts to serve the unmet medical needs of cancer patients.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology. The epigenetic/anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, Cyclacel’s future plans and prospects, Cyclacel’s anticipated cash runway and the planned timing of data results and continued development of plogosertib. Factors that may cause actual results to differ materially include market and other conditions, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates and Cyclacel’s ability to regain and maintain compliance with Nasdaq’s continued listing requirements, although no assurance to that effect can be given. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Cyclacel Pharmaceuticals, Inc.
Datuk Dr. Doris Wong Sing Ee
Chief Executive Officer
Tel: (908) 517-7330
Email: [email protected]

© Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.

SOURCE:
Cyclacel Pharmaceuticals, Inc.

CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)
(In $000s, except share and per share amounts)
 
  Three Months Ended   Twelve Months Ended
  December 31,   December 31,
  2024   2023   2024   2023
               
Revenues:              
Collaboration and research and development revenue         31       43       420  
Revenues $     $ 31     $ 43     $ 420  
               
Operating expenses:              
Research and development   880       3,519       6,655       19,155  
General and administrative   946       1,873       5,392       6,718  
Total operating expenses   1,826       5,392       12,047       25,873  
Operating loss   (1,826 )     (5,361 )     (12,004 )     (25,453 )
Other income (expense):              
Foreign exchange gains (losses)   (60 )     (355 )     (54 )     (414 )
Interest income   30       23       12       266  
Other income, net         (1 )     52       50  
Total other income (expense), net   (30 )     (333 )     10       (98 )
Loss before taxes   (1,856 )     (5,694 )     (11,994 )     (25,551 )
Income tax benefit   (1,194 )     422       782       2,996  
Net loss   (3,050 )     (5,272 )     (11,212 )     (22,555 )
Dividend on convertible exchangeable preferred shares         (50 )           (201 )
Net loss applicable to common shareholders $ (3,050 )   $ (5,322 )   $ (11,212 )   $ (22,756 )
Basic and diluted earnings per common share:              
Net loss per share – basic and diluted (common shareholders) $ (0.33 )   $ (6.16 )   $ (2.09 )   $ (26.75 )
                               

CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEET
(In $000s, except share, per share, and liquidation preference amounts)
 
  December 31,


  December 31,


  2024
  2023
       
ASSETS      
Current assets:      
Cash and cash equivalents $ 3,137     $ 3,378
Prepaid expenses and other current assets   537       4,066
Total current assets   3,674       7,444
       
Property and equipment, net   3       9
Right-of-use lease asset   5       93
Non-current deposits   412       1,259
Total assets $ 4,094     $ 8,805
       
LIABILITIES AND STOCKHOLDERS’ EQUITY      
Current liabilities:      
Accounts payable $ 4,599     $ 3,543
Accrued and other current liabilities   1,669       4,618
Total current liabilities   6,268       8,161
Lease liability         37
Total liabilities   6,268       8,198
       
Stockholders’ equity   (2,174 )     607
Total liabilities and stockholders’ equity $ 4,094     $ 8,805



Penguin Solutions Reports Q2 Fiscal 2025 Financial Results

Penguin Solutions Reports Q2 Fiscal 2025 Financial Results

Revenue up 28% compared with year-ago quarter

Company raises midpoint of annual revenue outlook

MILPITAS, Calif.–(BUSINESS WIRE)–
Penguin Solutions, Inc. (“Penguin Solutions,” “we,” “us,” or the “Company”) (NASDAQ: PENG) today reported financial results for the second quarter of fiscal 2025 and announced the planned retirement of Chief Operating Officer (“COO”) and President of Integrated Memory Jack Pacheco.

Second Quarter Fiscal 2025 Highlights

  • Net sales of $366 million, up 28.3% versus the year-ago quarter
  • GAAP gross margin of 28.6%, down 20 basis points versus the year-ago quarter
  • Non-GAAP gross margin of 30.8%, down 70 basis points versus the year-ago quarter
  • GAAP diluted EPS of $0.09 versus $(0.26) in the year-ago quarter
  • Non-GAAP diluted EPS of $0.52 versus $0.27 in the year-ago quarter

“We are pleased with the progress we are making in fiscal year 2025,” said Mark Adams, Chief Executive Officer (“CEO”) of Penguin Solutions. “Our results reinforce our capabilities in managing the complexity of AI for our valued customers. Given our strong start to the fiscal year, we are raising the midpoint of our revenue outlook for the full year.”

Quarterly Financial Results

 

GAAP (1)

 

Non-GAAP (2)

(in thousands, except per share amounts)

Q2-25

 

Q1-25

 

Q2-24

 

Q2-25

 

Q1-25

 

Q2-24

Net sales:

 

 

 

 

 

 

 

 

 

 

 

Advanced Computing

$

200,157

 

$

177,426

 

$

141,405

 

 

$

200,157

 

$

177,426

 

$

141,405

Integrated Memory

 

105,260

 

 

96,706

 

 

83,297

 

 

 

105,260

 

 

96,706

 

 

83,297

Optimized LED

 

60,102

 

 

66,970

 

 

60,119

 

 

 

60,102

 

 

66,970

 

 

60,119

Total net sales

$

365,519

 

$

341,102

 

$

284,821

 

 

$

365,519

 

$

341,102

 

$

284,821

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

$

104,648

 

$

97,812

 

$

81,934

 

 

$

112,408

 

$

105,122

 

$

89,735

Operating income (loss)

 

18,488

 

 

17,356

 

 

(3,312

)

 

 

49,090

 

 

40,918

 

 

26,514

Net income (loss) attributable to Penguin Solutions

 

8,082

 

 

5,217

 

 

(13,620

)

 

 

33,836

 

 

26,518

 

 

14,141

Diluted earnings (loss) per share

$

0.09

 

$

0.10

 

$

(0.26

)

 

$

0.52

 

$

0.49

 

$

0.27

(1)

 

GAAP represents U.S. Generally Accepted Accounting Principles.

(2)

 

Non-GAAP represents GAAP excluding the impact of certain activities. Further information regarding the Company’s use of non-GAAP measures and reconciliations between GAAP and non-GAAP measures are included within this press release.

Business Outlook

As of April 2, 2025, Penguin Solutions is providing the following financial outlook for fiscal year 2025:

New Outlook

GAAP

Outlook

Adjustments

Non-GAAP

Outlook

Net sales

17% YoY Growth +/- 3%

17% YoY Growth +/- 3%

Gross margin

29% +/- 1%

2%

(A)

31% +/- 1%

Operating expenses

$336 million +/- $5 million

($71) million

(B)(C)(D)

$265 million +/- $5 million

Diluted earnings per share

$-0.02 +/- $0.10

$1.62

(A)(B)(C)(D)(E)

$1.60 +/- $0.10

Diluted shares

54 million

1 million

55 million

Non-GAAP adjustments (in millions)

 

(A) Share-based compensation and amortization of acquisition-related intangibles included in cost of sales

$

31

 

(B) Share-based compensation and amortization of acquisition-related intangibles included in R&D and SG&A

 

48

 

(C) Goodwill impairment

 

16

 

(D) Other adjustments

 

7

 

(E) Estimated income tax effects

 

(13

)

 

$

89

 

Prior Outlook

GAAP

Outlook

Adjustments

Non-GAAP

Outlook

Net sales

15% YoY Growth +/- 5%

15% YoY Growth +/- 5%

Gross margin

30% +/- 1%

2%

(A)

32% +/- 1%

Operating expenses

$335 million +/- $15 million

($60) million

(B)(C)

$275 million +/- $15 million

Diluted earnings per share

$0.10 +/- $0.20

$1.40

(A)(B)(C)(D)

$1.50 +/- $0.20

Diluted shares

56.3 million

56.3 million

Non-GAAP adjustments (in millions)

 

(A) Share-based compensation and amortization of acquisition-related intangibles included in cost of sales

$

31

 

(B) Share-based compensation and amortization of acquisition-related intangibles included in R&D and SG&A

 

48

 

(C) Other adjustments

 

12

 

(D) Estimated income tax effects

 

(12

)

 

$

79

 

Second Quarter Fiscal 2025 Earnings Conference Call and Webcast Details

Penguin Solutions will hold a conference call and webcast to discuss the second quarter of fiscal 2025 results and related matters today, April 2, 2025, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Interested parties may access the call by dialing +1-833-470-1428 in the United States or +1-404-975-4839 from international locations, using the access code 858614. The earnings presentation and a live webcast of the conference call can be accessed from the Company’s investor relations website (https://ir.penguinsolutions.com/investors/default.aspx) where they will remain available for approximately one year.

Jack Pacheco to Retire as Chief Operating Officer and President of Integrated Memory

Jack Pacheco, Executive Vice President (“EVP”), COO and President of Integrated Memory, is expected to retire from the Company on December 31, 2025. The Company has initiated a succession planning process. Mr. Pacheco is expected to transition into a special advisor role if his successor is appointed before his retirement, and to provide consulting services following his retirement to ensure continuity and a smooth transition of his responsibilities.

Mr. Pacheco first joined the Company in 1994 and has served in various leadership roles during his tenure. He remained with the Company from 1994 until 2001, and then returned in 2004 as Chief Financial Officer (“CFO”), a position he held until 2008. In 2011, Mr. Pacheco returned to the Company and served as Senior Vice President, COO and CFO until becoming EVP, COO and President of Integrated Memory in September 2020.

“On behalf of the entire company, I want to thank Jack for his nearly 25 years of leadership and dedication,” said Mark Adams, CEO of Penguin Solutions. “Jack played a key role in scaling our memory business and strengthening our global operations. We’re grateful for his many contributions and his support through this transition.”

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements concerning or regarding future events and the future financial and operating performance of Penguin Solutions; statements regarding the extent and timing of and expectations regarding Penguin Solutions’ future revenues and expenses; statements regarding Penguin Solutions’ strategic transformation and priorities; statements regarding long-term effective tax rates; statements regarding the business and financial outlook for fiscal year 2025 described under “Business Outlook” above; and statements regarding the expected retirement of Mr. Pacheco and related succession planning activities.

These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements often use words such as “anticipate,” “target,” “expect,” “estimate,” “intend,” “plan,” “goal,” “believe,” “could,” and other words of similar meaning. Forward-looking statements provide our current expectations or forecasts of future events, circumstances, results or aspirations and are subject to a number of significant risks, uncertainties and other factors, many of which are outside of our control, including but not limited to: global business and economic conditions and growth trends in technology industries (including trends and markets related to artificial intelligence), our customer markets and various geographic regions; uncertainties in the geopolitical environment; the ability to manage our cost structure; disruptions in our operations or supply chain as a result of global pandemics or otherwise; changes in trade regulations or adverse developments in international trade relations and agreements; changes in currency exchange rates; overall information technology spending; appropriations for government spending; the success of our strategic initiatives including our proposed redomiciliation to the United States (which remains subject to shareholder and court approval), our rebranding and related strategy, any existing or potential collaborations and additional investments in new products and additional capacity; acquisitions of companies or technologies and the failure to successfully integrate and operate them or customers’ negative reactions to them; issues, delays or complications in integrating the operations of Stratus Technologies; failure to achieve the intended benefits of the sale of SMART Brazil and its business; limitations on or changes in the availability of supply of materials and components; fluctuations in material costs; the temporary or volatile nature of pricing trends in memory or elsewhere; deterioration in customer relationships; our dependence on a select number of customers and the timing and volume of customer orders; production or manufacturing difficulties; competitive factors; technological changes; difficulties with, or delays in, the introduction of new products; slowing or contraction of growth in the memory market, LED market or other markets in which we participate; changes to applicable tax regimes or rates; changes to the valuation allowance for our deferred tax assets, including any potential inability to realize these assets in the future; prices for the end products of our customers; strikes or labor disputes; deterioration in or loss of relations with any of our limited number of key vendors; the inability to maintain or expand government business; and the continuing availability of borrowings under term loans and revolving lines of credit and our ability to raise capital through debt or equity financings.

These and other risks, uncertainties and factors are described in greater detail under the sections titled “Risk Factors,” “Critical Accounting Estimates,” “Results of Operations,” “Quantitative and Qualitative Disclosures About Market Risk” and “Liquidity and Capital Resources” contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and our other filings with the U.S. Securities and Exchange Commission. In addition, such risks, uncertainties and factors as outlined above and in such filings do not constitute all risks, uncertainties and factors that could cause our actual results to be materially different from such forward-looking statements. Accordingly, investors are cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we do not undertake to update the forward-looking statements contained in this press release to reflect the impact of circumstances or events that may arise after the date that the forward-looking statements were made.

Statement Regarding Use of Non-GAAP Financial Measures

This press release and the accompanying tables contain the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income, non-GAAP effective tax rate, non-GAAP net income, non-GAAP weighted-average shares outstanding, non-GAAP diluted earnings per share and adjusted EBITDA. Penguin Solutions’ management uses these non-GAAP measures to supplement Penguin Solutions’ financial results under GAAP. Management uses these measures to analyze its operations and make decisions as to future operational plans and believes that this supplemental non-GAAP information is useful to investors in analyzing and assessing the Company’s past and future operating performance. These non-GAAP measures exclude certain items, such as share-based compensation expense; amortization of acquisition-related intangible assets (consisting of amortization of developed technology, customer relationships and trademarks/trade names acquired in connection with business combinations); cost of sales-related restructuring; diligence, acquisition and integration expense; redomiciliation costs; restructuring charges; impairment of goodwill; changes in the fair value of contingent consideration; gains (losses) from changes in foreign currency exchange rates; amortization of debt issuance costs; gain (loss) on extinguishment or prepayment of debt; other infrequent or unusual items and related tax effects and other tax adjustments. While amortization of acquisition-related intangible assets is excluded, the revenues from acquired companies are reflected in the Company’s non-GAAP measures and these intangible assets contribute to revenue generation. Management believes the presentation of operating results that exclude certain items provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses adjusted EBITDA, which represents GAAP net income (loss), adjusted for net interest expense; income tax provision (benefit); depreciation expense and amortization of intangible assets; share-based compensation expense; cost of sales-related restructuring; diligence, acquisition and integration expense; redomiciliation costs; impairment of goodwill; restructuring charges; loss on extinguishment of debt and other infrequent or unusual items.

In fiscal 2024, for our non-GAAP reporting, we began to utilize a long-term projected non-GAAP effective tax rate of 28%, which includes the tax impact of pre-tax non-GAAP adjustments and reflects currently available information as well as other factors and assumptions. While we expect to use this normalized non-GAAP effective tax rate through fiscal 2025, this long-term non-GAAP effective tax rate may be subject to change for a variety of reasons, including the rapidly evolving global tax environment, significant changes in our geographic earnings mix or changes to our strategy or business operations. Our GAAP effective tax rate can vary significantly from quarter to quarter based on a variety of factors, including, but not limited to, discrete items which are recorded in the period they occur, the tax effects of certain items of income or expense, significant changes in our geographic earnings mix or changes to our strategy or business operations. We are unable to predict the timing and amounts of these items, which could significantly impact our GAAP effective tax rate, and therefore we are unable to reconcile our forward-looking non-GAAP effective tax rate measure to our GAAP effective tax rate.

Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP, as they exclude important information about Penguin Solutions’ financial results, as noted above. The presentation of these adjusted amounts varies from amounts presented in accordance with GAAP and therefore may not be comparable to amounts reported by other companies. In addition, adjusted EBITDA does not purport to represent cash flow provided by, or used for, operating activities in accordance with GAAP and should not be used as a measure of liquidity. Investors are encouraged to review the “Reconciliation of GAAP to Non-GAAP Measures” tables below.

About Penguin Solutions

The most exciting technological advancements are also the most challenging for companies to adopt. At Penguin Solutions, we support our customers in achieving their ambitions across our computing, memory, and LED lines of business. With our expert skills, experience, and partnerships, we turn our customers’ most complex challenges into compelling opportunities.

For more information, visit www.penguinsolutions.com.

Penguin Solutions, Inc.

Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited) 

 

Three Months Ended

 

Six Months Ended

 

February 28,

2025

 

November 29,

2024

 

March 1,

2024

 

February 28,

2025

 

March 1,

2024

Net sales:

 

 

 

 

 

 

 

 

 

Advanced Computing

$

200,157

 

 

$

177,426

 

$

141,405

 

 

$

377,583

 

$

260,229

 

Integrated Memory

 

105,260

 

 

 

96,706

 

 

83,297

 

 

 

201,966

 

 

168,965

 

Optimized LED

 

60,102

 

 

 

66,970

 

 

60,119

 

 

 

127,072

 

 

129,874

 

Total net sales

 

365,519

 

 

 

341,102

 

 

284,821

 

 

 

706,621

 

 

559,068

 

Cost of sales

 

260,871

 

 

 

243,290

 

 

202,887

 

 

 

504,161

 

 

394,284

 

Gross profit

 

104,648

 

 

 

97,812

 

 

81,934

 

 

 

202,460

 

 

164,784

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

19,907

 

 

 

19,811

 

 

20,526

 

 

 

39,718

 

 

41,915

 

Selling, general and administrative

 

59,315

 

 

 

60,536

 

 

61,385

 

 

 

119,851

 

 

118,602

 

Impairment of goodwill

 

6,079

 

 

 

 

 

 

 

 

6,079

 

 

 

Other operating expense

 

859

 

 

 

109

 

 

3,335

 

 

 

968

 

 

6,274

 

Total operating expenses

 

86,160

 

 

 

80,456

 

 

85,246

 

 

 

166,616

 

 

166,791

 

Operating income (loss)

 

18,488

 

 

 

17,356

 

 

(3,312

)

 

 

35,844

 

 

(2,007

)

 

 

 

 

 

 

 

 

 

 

Non-operating (income) expense:

 

 

 

 

 

 

 

 

 

Interest expense, net

 

2,183

 

 

 

4,396

 

 

7,249

 

 

 

6,579

 

 

16,808

 

Other non-operating (income) expense

 

(209

)

 

 

636

 

 

248

 

 

 

427

 

 

(328

)

Total non-operating (income) expense

 

1,974

 

 

 

5,032

 

 

7,497

 

 

 

7,006

 

 

16,480

 

Income (loss) before taxes

 

16,514

 

 

 

12,324

 

 

(10,809

)

 

 

28,838

 

 

(18,487

)

 

 

 

 

 

 

 

 

 

 

Income tax provision

 

7,643

 

 

 

6,360

 

 

2,198

 

 

 

14,003

 

 

5,732

 

Net income (loss) from continuing operations

 

8,871

 

 

 

5,964

 

 

(13,007

)

 

 

14,835

 

 

(24,219

)

Net loss from discontinued operations

 

 

 

 

 

 

 

 

 

 

 

(8,148

)

Net income (loss)

 

8,871

 

 

 

5,964

 

 

(13,007

)

 

 

14,835

 

 

(32,367

)

Net income attributable to noncontrolling interest

 

789

 

 

 

747

 

 

613

 

 

 

1,536

 

 

1,174

 

Net income (loss) attributable to Penguin Solutions

 

8,082

 

 

 

5,217

 

 

(13,620

)

 

 

13,299

 

 

(33,541

)

 

 

 

 

 

 

 

 

 

 

Preferred share dividends

 

2,600

 

 

 

 

 

 

 

 

2,600

 

 

 

Income available for distribution

 

5,482

 

 

 

5,217

 

 

(13,620

)

 

 

10,699

 

 

(33,541

)

Income allocated to participating securities

 

482

 

 

 

 

 

 

 

 

492

 

 

 

Net income available to ordinary shareholders

$

5,000

 

 

$

5,217

 

$

(13,620

)

 

$

10,207

 

$

(33,541

)

 

 

 

 

 

 

 

 

 

 

Basic earnings (loss) per share:

 

 

 

 

 

 

 

 

 

Continuing operations

$

0.09

 

 

$

0.10

 

$

(0.26

)

 

$

0.19

 

$

(0.49

)

Discontinued operations

 

 

 

 

 

 

 

 

 

 

 

(0.15

)

 

$

0.09

 

 

$

0.10

 

$

(0.26

)

 

$

0.19

 

$

(0.64

)

 

 

 

 

 

 

 

 

 

 

Diluted earnings (loss) per share:

 

 

 

 

 

 

 

 

 

Continuing operations

$

0.09

 

 

$

0.10

 

$

(0.26

)

 

$

0.19

 

$

(0.49

)

Discontinued operations

 

 

 

 

 

 

 

 

 

 

 

(0.15

)

 

$

0.09

 

 

$

0.10

 

$

(0.26

)

 

$

0.19

 

$

(0.64

)

 

 

 

 

 

 

 

 

 

 

Shares used in per share calculations:

 

 

 

 

 

 

 

 

 

Basic

 

53,454

 

 

 

53,482

 

 

52,031

 

 

 

53,468

 

 

52,050

 

Diluted

 

54,384

 

 

 

54,312

 

 

52,031

 

 

 

54,484

 

 

52,050

 

Penguin Solutions, Inc.

Reconciliation of GAAP to Non-GAAP Measures

(In thousands, except percentages)

(Unaudited) 

 

Three Months Ended

 

Six Months Ended

 

February 28,

2025

 

November 29,

2024

 

March 1,

2024

 

February 28,

2025

 

March 1,

2024

GAAP gross profit

$

104,648

 

 

$

97,812

 

 

$

81,934

 

 

$

202,460

 

 

$

164,784

 

Share-based compensation expense

 

1,776

 

 

 

1,643

 

 

 

1,691

 

 

 

3,419

 

 

 

3,506

 

Amortization of acquisition-related intangibles

 

5,907

 

 

 

5,909

 

 

 

5,894

 

 

 

11,816

 

 

 

11,838

 

Cost of sales-related restructuring

 

77

 

 

 

(42

)

 

 

216

 

 

 

35

 

 

 

884

 

Other

 

 

 

 

(200

)

 

 

 

 

 

(200

)

 

 

 

Non-GAAP gross profit

$

112,408

 

 

$

105,122

 

 

$

89,735

 

 

$

217,530

 

 

$

181,012

 

 

 

 

 

 

 

 

 

 

 

GAAP gross margin

 

28.6

%

 

 

28.7

%

 

 

28.8

%

 

 

28.7

%

 

 

29.5

%

Effect of adjustments

 

2.2

%

 

 

2.1

%

 

 

2.7

%

 

 

2.1

%

 

 

2.9

%

Non-GAAP gross margin

 

30.8

%

 

 

30.8

%

 

 

31.5

%

 

 

30.8

%

 

 

32.4

%

 

 

 

 

 

 

 

 

 

 

GAAP operating expenses

$

86,160

 

 

$

80,456

 

 

$

85,246

 

 

$

166,616

 

 

$

166,791

 

Share-based compensation expense

 

(9,804

)

 

 

(9,888

)

 

 

(8,948

)

 

 

(19,692

)

 

 

(18,103

)

Amortization of acquisition-related intangibles

 

(2,932

)

 

 

(3,846

)

 

 

(3,857

)

 

 

(6,778

)

 

 

(7,921

)

Diligence, acquisition and integration expense

 

(567

)

 

 

(833

)

 

 

(5,885

)

 

 

(1,400

)

 

 

(6,674

)

Redomiciliation costs (1)

 

(2,359

)

 

 

(1,243

)

 

 

 

 

 

(3,602

)

 

 

 

Impairment of goodwill

 

(6,079

)

 

 

 

 

 

 

 

 

(6,079

)

 

 

 

Restructuring charges

 

(859

)

 

 

(109

)

 

 

(3,335

)

 

 

(968

)

 

 

(6,274

)

Other (1)

 

(242

)

 

 

(333

)

 

 

 

 

 

(575

)

 

 

 

Non-GAAP operating expenses

$

63,318

 

 

$

64,204

 

 

$

63,221

 

 

$

127,522

 

 

$

127,819

 

 

 

 

 

 

 

 

 

 

 

GAAP operating income (loss)

$

18,488

 

 

$

17,356

 

 

$

(3,312

)

 

$

35,844

 

 

$

(2,007

)

Share-based compensation expense

 

11,580

 

 

 

11,531

 

 

 

10,639

 

 

 

23,111

 

 

 

21,609

 

Amortization of acquisition-related intangibles

 

8,839

 

 

 

9,755

 

 

 

9,751

 

 

 

18,594

 

 

 

19,759

 

Cost of sales-related restructuring

 

77

 

 

 

(42

)

 

 

216

 

 

 

35

 

 

 

884

 

Diligence, acquisition and integration expense

 

567

 

 

 

833

 

 

 

5,885

 

 

 

1,400

 

 

 

6,674

 

Redomiciliation costs (1)

 

2,359

 

 

 

1,243

 

 

 

 

 

 

3,602

 

 

 

 

Impairment of goodwill

 

6,079

 

 

 

 

 

 

 

 

 

6,079

 

 

 

 

Restructuring charges

 

859

 

 

 

109

 

 

 

3,335

 

 

 

968

 

 

 

6,274

 

Other (1)

 

242

 

 

 

133

 

 

 

 

 

 

375

 

 

 

 

Non-GAAP operating income

$

49,090

 

 

$

40,918

 

 

$

26,514

 

 

$

90,008

 

 

$

53,193

 

(1) In the second quarter of fiscal 2025 we began breaking out redomiciliation costs from “Other.” All periods presented have been adjusted to reflect this change.

Penguin Solutions, Inc.

Reconciliation of GAAP to Non-GAAP Measures

(In thousands, except per share amounts)

(Unaudited) 

 

Three Months Ended

 

Six Months Ended

 

February 28,

2025

 

November 29,

2024

 

March 1,

2024

 

February 28,

2025

 

March 1,

2024

GAAP net income (loss) attributable to Penguin Solutions

$

8,082

 

 

$

5,217

 

 

$

(13,620

)

 

$

13,299

 

 

$

(25,393

)

Share-based compensation expense

 

11,580

 

 

 

11,531

 

 

 

10,639

 

 

 

23,111

 

 

 

21,609

 

Amortization of acquisition-related intangibles

 

8,839

 

 

 

9,755

 

 

 

9,751

 

 

 

18,594

 

 

 

19,759

 

Cost of sales-related restructuring

 

77

 

 

 

(42

)

 

 

216

 

 

 

35

 

 

 

884

 

Diligence, acquisition and integration expense

 

567

 

 

 

833

 

 

 

5,885

 

 

 

1,400

 

 

 

6,674

 

Redomiciliation costs (1)

 

2,359

 

 

 

1,243

 

 

 

 

 

 

3,602

 

 

 

 

Impairment of goodwill

 

6,079

 

 

 

 

 

 

 

 

 

6,079

 

 

 

 

Restructuring charges

 

859

 

 

 

109

 

 

 

3,335

 

 

 

968

 

 

 

6,274

 

Amortization of debt issuance costs

 

950

 

 

 

953

 

 

 

968

 

 

 

1,903

 

 

 

2,010

 

Loss (gain) on extinguishment or prepayment of debt

 

 

 

 

 

 

 

325

 

 

 

 

 

 

325

 

Foreign currency (gains) losses

 

24

 

 

 

1,028

 

 

 

182

 

 

 

1,052

 

 

 

(364

)

Other (1)

 

242

 

 

 

133

 

 

 

 

 

 

375

 

 

 

 

Income tax effects

 

(5,822

)

 

 

(4,242

)

 

 

(3,540

)

 

 

(10,064

)

 

 

(5,099

)

Non-GAAP net income attributable to Penguin Solutions

 

33,836

 

 

 

26,518

 

 

 

14,141

 

 

 

60,354

 

 

 

26,679

 

 

 

 

 

 

 

 

 

 

 

Preferred share dividends

 

2,600

 

 

 

 

 

 

 

 

 

2,600

 

 

 

 

Non-GAAP income available for distribution

 

31,236

 

 

 

26,518

 

 

 

14,141

 

 

 

57,754

 

 

 

29,887

 

Income allocated to participating securities

 

2,706

 

 

 

 

 

 

 

 

 

2,610

 

 

 

 

Non-GAAP net income available to ordinary shareholders

$

28,530

 

 

$

26,518

 

 

$

14,141

 

 

$

55,144

 

 

$

29,887

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding – Diluted:

 

 

 

 

 

 

 

 

 

GAAP weighted-average shares outstanding

 

54,384

 

 

 

54,312

 

 

 

52,031

 

 

 

54,484

 

 

 

52,050

 

Adjustment for dilutive securities and capped calls

 

 

 

 

 

 

 

1,043

 

 

 

 

 

 

1,128

 

Non-GAAP weighted-average shares outstanding

 

54,384

 

 

 

54,312

 

 

 

53,074

 

 

 

54,484

 

 

 

53,178

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings (loss) per share from continuing operations:

 

 

 

 

 

 

 

 

 

GAAP diluted earnings (loss) per share

$

0.09

 

 

$

0.10

 

 

$

(0.26

)

 

$

0.19

 

 

$

(0.49

)

Effect of adjustments

 

0.43

 

 

 

0.39

 

 

 

0.53

 

 

 

0.82

 

 

 

0.99

 

Non-GAAP diluted earnings per share

$

0.52

 

 

$

0.49

 

 

$

0.27

 

 

$

1.01

 

 

$

0.50

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Penguin Solutions

$

8,082

 

 

$

5,217

 

 

$

(13,620

)

 

$

13,299

 

 

$

(25,393

)

Interest expense, net

 

2,183

 

 

 

4,396

 

 

 

7,249

 

 

 

6,579

 

 

 

16,808

 

Income tax provision (benefit)

 

7,643

 

 

 

6,360

 

 

 

2,198

 

 

 

14,003

 

 

 

5,732

 

Depreciation expense and amortization of intangible assets

 

14,037

 

 

 

14,961

 

 

 

17,156

 

 

 

28,998

 

 

 

34,810

 

Share-based compensation expense

 

11,580

 

 

 

11,531

 

 

 

10,639

 

 

 

23,111

 

 

 

21,609

 

Cost of sales-related restructuring

 

77

 

 

 

(42

)

 

 

216

 

 

 

35

 

 

 

884

 

Diligence, acquisition and integration expense

 

567

 

 

 

833

 

 

 

5,885

 

 

 

1,400

 

 

 

6,674

 

Redomiciliation costs (1)

 

2,359

 

 

 

1,243

 

 

 

 

 

 

3,602

 

 

 

 

Impairment of goodwill

 

6,079

 

 

 

 

 

 

 

 

 

6,079

 

 

 

 

Restructuring charges

 

859

 

 

 

109

 

 

 

3,335

 

 

 

968

 

 

 

6,274

 

Loss on extinguishment of debt

 

 

 

 

 

 

 

325

 

 

 

 

 

 

325

 

Other (1)

 

242

 

 

 

133

 

 

 

 

 

 

375

 

 

 

 

Adjusted EBITDA

$

53,708

 

 

$

44,741

 

 

$

33,383

 

 

$

98,449

 

 

$

67,723

 

(1) In the second quarter of fiscal 2025 we began breaking out redomiciliation costs from “Other.” All periods presented have been adjusted to reflect this change.

Penguin Solutions, Inc.

Consolidated Balance Sheets

(In thousands)

(Unaudited) 

As of

February 28,

2025

 

August 30,

2024

Assets

 

 

 

Cash and cash equivalents

$

621,682

 

 

$

383,147

 

Short-term investments

 

25,323

 

 

 

6,337

 

Accounts receivable, net

 

330,384

 

 

 

251,743

 

Inventories

 

199,737

 

 

 

151,213

 

Other current assets

 

67,639

 

 

 

75,264

 

Total current assets

 

1,244,765

 

 

 

867,704

 

Property and equipment, net

 

97,116

 

 

 

106,548

 

Operating lease right-of-use assets

 

56,363

 

 

 

60,349

 

Intangible assets, net

 

103,280

 

 

 

121,454

 

Goodwill

 

155,879

 

 

 

161,958

 

Deferred tax assets

 

84,944

 

 

 

85,078

 

Other noncurrent assets

 

68,997

 

 

 

71,415

 

Total assets

$

1,811,344

 

 

$

1,474,506

 

 

 

 

 

Liabilities and Equity

 

 

 

Accounts payable and accrued expenses

$

278,093

 

 

$

219,090

 

Current debt

 

19,891

 

 

 

 

Deferred revenue

 

121,646

 

 

 

63,954

 

Other current liabilities

 

54,075

 

 

 

44,552

 

Total current liabilities

 

473,705

 

 

 

327,596

 

Long-term debt

 

638,900

 

 

 

657,347

 

Noncurrent operating lease liabilities

 

56,816

 

 

 

60,542

 

Other noncurrent liabilities

 

30,032

 

 

 

29,813

 

Total liabilities

 

1,199,453

 

 

 

1,075,298

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

Penguin Solutions shareholders’ equity:

 

 

 

Preferred shares

 

6

 

 

 

 

Ordinary shares

 

1,849

 

 

 

1,807

 

Additional paid-in capital

 

731,323

 

 

 

513,335

 

Retained earnings

 

40,684

 

 

 

29,985

 

Treasury shares

 

(171,351

)

 

 

(153,756

)

Accumulated other comprehensive income (loss)

 

17

 

 

 

10

 

Total Penguin Solutions shareholders’ equity

 

602,528

 

 

 

391,381

 

Noncontrolling interest in subsidiary

 

9,363

 

 

 

7,827

 

Total equity

 

611,891

 

 

 

399,208

 

Total liabilities and equity

$

1,811,344

 

 

$

1,474,506

 

Penguin Solutions, Inc.

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited) 

 

Three Months Ended

 

Six Months Ended

 

February 28,

2025

 

November 29,

2024

 

March 1,

2024

 

February 28,

2025

 

March 1,

2024

Cash flows from operating activities

 

 

 

 

 

 

 

 

 

Net income (loss)

$

8,871

 

 

$

5,964

 

 

$

(13,007

)

 

$

14,835

 

 

$

(32,367

)

Net loss from discontinued operations

 

 

 

 

 

 

 

 

 

 

 

 

 

(8,148

)

Net income (loss) from continuing operations

 

8,871

 

 

 

5,964

 

 

 

(13,007

)

 

 

14,835

 

 

 

(24,219

)

Adjustments to reconcile net income (loss) from continuing operations to cash provided by (used for) operating activities

 

 

 

 

 

 

 

 

 

Depreciation expense and amortization of intangible assets

 

14,037

 

 

 

14,961

 

 

 

17,156

 

 

 

28,998

 

 

 

34,810

 

Amortization of debt issuance costs

 

950

 

 

 

953

 

 

 

968

 

 

 

1,903

 

 

 

2,010

 

Share-based compensation expense

 

11,580

 

 

 

11,531

 

 

 

10,639

 

 

 

23,111

 

 

 

21,609

 

Impairment of goodwill

 

6,079

 

 

 

 

 

 

 

 

 

6,079

 

 

 

 

Loss on extinguishment or prepayment of debt

 

 

 

 

 

 

 

325

 

 

 

 

 

 

325

 

Deferred income taxes, net

 

(48

)

 

 

211

 

 

 

476

 

 

 

163

 

 

 

194

 

Other

 

(716

)

 

 

(712

)

 

 

(208

)

 

 

(1,428

)

 

 

456

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

Accounts receivable

 

(54,755

)

 

 

(23,885

)

 

 

872

 

 

 

(78,640

)

 

 

49,530

 

Inventories

 

47,215

 

 

 

(93,380

)

 

 

35,678

 

 

 

(46,165

)

 

 

2,214

 

Other assets

 

15,015

 

 

 

705

 

 

 

(23,229

)

 

 

15,720

 

 

 

(21,127

)

Accounts payable and accrued expenses and other liabilities

 

24,649

 

 

 

97,471

 

 

 

(22,587

)

 

 

122,120

 

 

 

994

 

Payment of acquisition-related contingent consideration

 

 

 

 

 

 

 

(29,000

)

 

 

 

 

 

(29,000

)

Net cash provided by (used for) operating activities from continuing operations

 

72,877

 

 

 

13,819

 

 

 

(21,917

)

 

 

86,696

 

 

 

37,796

 

Net cash used for operating activities from discontinued operations

 

 

 

 

 

 

 

 

 

 

 

 

 

(28,235

)

Net cash provided by (used for) operating activities

 

72,877

 

 

 

13,819

 

 

 

(21,917

)

 

 

86,696

 

 

 

9,561

 

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

 

 

 

Capital expenditures and deposits on equipment

 

(2,335

)

 

 

(1,836

)

 

 

(5,204

)

 

 

(4,171

)

 

 

(9,852

)

Proceeds from maturities of investment securities

 

11,055

 

 

 

3,780

 

 

 

12,290

 

 

 

14,835

 

 

 

21,955

 

Purchases of held-to-maturity investment securities

 

(12,671

)

 

 

(20,723

)

 

 

(11,034

)

 

 

(33,394

)

 

 

(19,503

)

Purchases of non-marketable investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

(398

)

 

 

(143

)

 

 

(558

)

 

 

(541

)

 

 

(746

)

Net cash used for investing activities from continuing operations

 

(4,349

)

 

 

(18,922

)

 

 

(4,506

)

 

 

(23,271

)

 

 

(8,146

)

Net cash provided by investing activities from discontinued operations

 

 

 

 

 

 

 

 

 

 

 

 

 

118,938

 

Net cash provided by (used for) investing activities

$

(4,349

)

 

$

(18,922

)

 

$

(4,506

)

 

$

(23,271

)

 

$

110,792

 

Penguin Solutions, Inc.

Consolidated Statements of Cash Flows, Continued

(In thousands)

(Unaudited)

 

Three Months Ended

 

Six Months Ended

 

February 28,

2025

 

November 29,

2024

 

March 1,

2024

 

February 28,

2025

 

March 1,

2024

Cash flows from financing activities

 

 

 

 

 

 

 

 

 

Proceeds from issuance of convertible preferred shares, net of issuance costs

$

191,182

 

 

$

 

 

$

 

 

$

191,182

 

 

$

 

Repayments of debt

 

 

 

 

 

 

 

(37,211

)

 

 

 

 

 

(51,634

)

Payment of acquisition-related contingent consideration

 

 

 

 

 

 

 

(21,000

)

 

 

 

 

 

(21,000

)

Payments to acquire ordinary shares

 

(6,472

)

 

 

(11,123

)

 

 

(2,732

)

 

 

(17,595

)

 

 

(15,862

)

Payment of preferred share cash dividends

 

(2,233

)

 

 

 

 

 

 

 

 

(2,233

)

 

 

 

Distribution to noncontrolling interest

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,470

)

Proceeds from issuance of ordinary shares

 

382

 

 

 

3,360

 

 

 

792

 

 

 

3,742

 

 

 

4,247

 

Other

 

 

 

 

 

 

 

(1

)

 

 

 

 

 

(583

)

Net cash used for financing activities from continuing operations

 

182,859

 

 

 

(7,763

)

 

 

(60,152

)

 

 

175,096

 

 

 

(86,302

)

Net cash used for financing activities from discontinued operations

 

 

 

 

 

 

 

 

 

 

 

 

 

(606

)

Net cash used for financing activities

 

182,859

 

 

 

(7,763

)

 

 

(60,152

)

 

 

175,096

 

 

 

(86,908

)

 

 

 

 

 

 

 

 

 

 

Effect of changes in currency exchange rates

 

 

 

 

 

 

 

(155

)

 

 

 

 

 

(1,180

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

251,387

 

 

 

(12,866

)

 

 

(86,730

)

 

 

238,521

 

 

 

32,265

 

Cash, cash equivalents and restricted cash at beginning of period

 

370,611

 

 

 

383,477

 

 

 

529,059

 

 

 

383,477

 

 

 

410,064

 

Cash, cash equivalents and restricted cash at end of period

$

621,998

 

 

$

370,611

 

 

$

442,329

 

 

$

621,998

 

 

$

442,329

 

 

Investor Contact:

Suzanne Schmidt

Investor Relations

+1-510-360-8596

[email protected]

PR Contact:

Maureen O’Leary

Director Communications

1-602-330-6846

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Software Networks Hardware Electronic Design Automation Data Management Technology Artificial Intelligence Semiconductor Security Engineering Manufacturing Telecommunications

MEDIA:

Logo
Logo

FormFactor Doubles Capacity at Taiwan Service Center to Meet Growing Demand

Strategic investment enhances local capabilities to elevate customer support and satisfaction with FormFactor products

LIVERMORE, Calif., April 02, 2025 (GLOBE NEWSWIRE) — FormFactor, Inc. (NASDAQ: FORM), a leading provider of test and measurement technologies for the semiconductor industry, is pleased to announce the significant expansion of its Taiwan Service Center. This strategic investment aims to enhance the company’s capabilities and better serve its customers in Taiwan and across Asia. The service center plays a pivotal role in supporting new technologies for chip manufacturers developing advanced packaging technologies driven by advancements in artificial intelligence (AI), high-performance computing (HPC), mobile, and automotive applications.

The newly expanded facility features double the cleanroom space and additional office areas, enabling FormFactor to streamline repair turnaround times and enhance its capabilities to serve the region’s rapid growth. This investment increases capacity to provide testing and repair services for FormFactor products, which are crucial to meeting the accelerating requirements in this important region.

“The expansion of our Taiwan Service Center demonstrates our ongoing commitment to meeting the semiconductor industry’s evolving demands,” said Mike Slessor, CEO of FormFactor. “With this expansion, we’ll be able to respond more quickly to customers’ needs, delivering more efficient, comprehensive, and reliable support that helps our customers maintain a competitive edge in an increasingly dynamic market.”

In addition to larger office and cleanroom spaces, the center offers expanded probe card services. The facility also includes a technology demo center to support customers in co-packaged optics technologies, showcasing state-of-the-art silicon photonics test technologies and their applications in next-generation semiconductor solutions.

About FormFactor

FormFactor, Inc. (NASDAQ: FORM), is a leading provider of essential test and measurement technologies along the full IC life cycle – from characterization, modeling, reliability, and design debug, to qualification and production test. Semiconductor companies rely upon FormFactor’s products and services to accelerate profitability by optimizing device performance and advancing yield knowledge. The Company serves customers through its network of facilities in Asia, Europe, and North America. For more information, visit the Company’s website at www.formfactor.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the federal securities laws. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those described in the forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the expansion of the service center and its impact on the market, the Company’s customers, and the Company’s capabilities and capacity. Forward-looking statements may contain words such as “may,” “might,” “will,” “expect,” “plan,” “anticipate,” “forecast,” and “continue,” the negative or plural of these words and similar expressions and include the assumptions that underlie such statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: success of the expansion; changes in demand for the Company’s testing and repair services in the region; market opportunity; supply chain and labor dynamics; other external economic and political factors; and other factors, including those set forth in the Company’s most current annual report on Form 10-K, quarterly reports on Form 10-Q and other filings by the Company with the U.S. Securities and Exchange Commission. In addition, there are varying barriers to international trade, including restrictive trade and export regulations such as the US-China restrictions, dynamic tariffs, trade disputes between the U.S. and other countries, and national security developments or tensions, that may substantially restrict or condition our sales to or in certain countries, increase the cost of doing business internationally, and disrupt our supply chain. No assurances can be given that any of the events anticipated by the forward-looking statements within this press release will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of the Company. Unless required by law, the Company is under no obligation (and expressly disclaims any such obligation) to update or revise its forward-looking statements whether as a result of new information, future events, or otherwise.


FormFactor Investor Contact

Stan Finkelstein

Investor Relations

(925) 290-4273

[email protected]



Kestra Medical Technologies, Ltd. to Report Third Quarter Fiscal 2025 Financial Results on April 14

KIRKLAND, Wash., April 02, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that it will report financial results for the third quarter fiscal 2025 on Monday, April 14. Management will host a corresponding conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

A live and archived webcast of the conference call will be available in the “Events” section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call.

About Kestra

Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.



Investor contact
Neil Bhalodkar
[email protected]

Pioneer Power to Host 2024 Fourth Quarter and Year End Financial Results Conference Call on Tuesday, April 15, 2025 at 4:30 p.m. ET

Pioneer Power to Host 2024 Fourth Quarter and Year End Financial Results Conference Call on Tuesday, April 15, 2025 at 4:30 p.m. ET

FORT LEE, N.J.–(BUSINESS WIRE)–
Pioneer Power Solutions, Inc. (Nasdaq: PPSI) (“Pioneer”), a leader in the design, manufacture, service and integration of distributed energy resources, power generation equipment and mobile electric vehicle (“EV”) charging solutions, today announced that management will host a conference call on Tuesday, April 15, 2025 at 4:30 p.m. Eastern Time to discuss Pioneer’s 2024 fourth quarter and year end financial results with the investment community. The company will release results for the fourth quarter and the year ended December 31, 2024 on Tuesday, April 15, 2025 after the markets close.

Anyone interested in participating should call 1-877-407-0789 if calling within the United States or 1-201-689-8562 if calling internationally. When asked, please reference confirmation code 13752590.

A replay will be available until April 22, 2025, which can be accessed by dialing 1-844-512-2921 if calling within the United States or 1-412-317-6671 if calling internationally. Please use passcode 13752590 to access the replay.

The call will also be accompanied live by webcast over the Internet and accessible at https://viavid.webcasts.com/starthere.jsp?ei=1712844&tp_key=c8ff18fe09.

About Pioneer Power Solutions, Inc.

Pioneer Power Solutions, Inc. is a leader in the design, manufacture, integration, service and distribution of electric power systems, distributed energy resources, power generation equipment and mobile electric charging solutions for applications in the utility, industrial and commercial markets. To learn more about Pioneer, please visit its website at www.pioneerpowersolutions.com.

e-Boost is Pioneer’s portfolio of smart, mobile EV charging solutions. The Company has been aggressively marketing e-Boost to electric bus and truck manufacturers, fleet management companies, municipalities and EV infrastructure providers since its initial launch in November 2021.

Brett Maas, Managing Partner

Hayden IR

(646) 536-7331

[email protected]

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Engineering Automotive Automotive Manufacturing Utilities EV/Electric Vehicles Manufacturing Energy

MEDIA:

Logo
Logo

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 73,325 shares of Akebia’s common stock on March 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $1.92 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco
[email protected]



RH Reports Fourth Quarter and Fiscal 2024 Results

RH Reports Fourth Quarter and Fiscal 2024 Results

CORTE MADERA, Calif.–(BUSINESS WIRE)–
RH (NYSE: RH) has released its financial results for the fourth quarter and fiscal year 2024 ended February 1, 2025, in a shareholder letter from Chairman and Chief Executive Officer Gary Friedman, available on the Investor Relations section of its website at ir.rh.com.

As previously announced, RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) today. The live conference call may be accessed by dialing 800.715.9871 or 646.307.1963 for international callers (conference ID: 8284432). The call and replay can also be accessed via audio webcast at ir.rh.com.

ABOUT RH

RH (NYSE: RH) is a curator of design, taste and style in the luxury lifestyle market. The Company offers collections through its retail galleries, sourcebooks, and online at RH.com, RHModern.RH.com, RHBabyandChild.RH.com, RHTEEN.RH.com and Waterworks.com.

PRESS CONTACT

[email protected]

INVESTOR RELATIONS CONTACT

Allison Malkin, 203.682.8225, [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Interior Design Retail Luxury Home Goods Specialty Construction & Property

MEDIA: